Beam Therapeutics Investor Relations Material
Latest events
Study Update
Beam Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Beam Therapeutics Inc
Access all reports
Segment Data
Access more data
Revenue by
Source
License and collaboration revenue
Expenses by
Financials
Beam Therapeutics Inc. operates as a clinical-stage biotechnology company, which develops base editing technology to treat serious diseases by making precise changes to DNA and RNA. Its portfolio includes target genes that cover oncology, hematology, ophthalmology, liver disease and neurology conditions. The company was founded by David Nelles, Matthew Porteus and Feng Zhang on April 10, 2018 and is headquartered in Cambridge, MA.
Key slides for Beam Therapeutics Inc
Study Update
Beam Therapeutics Inc
Study Update
Beam Therapeutics Inc
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
BEAM
Country
🇺🇸 United States